Imeglimin

Overview

Imeglimin has been used in trials studying the treatment of Type 2 Diabetes Mellitus.

Technical identifiers

Chemical Formula: C₆H₁₃N₅
CAS Number: 775351-65-0
UNII ID: UU226QGU97

Patents

One entry per invention. Patent families filed in the US, EP, WO and CN offices.

PROCESS FOR PREPARATION OF IMEGLIMIN AND SALTS THEREOF
EP 4514392 A4Applicant: HARMAN FINOCHEM LTDPriority: 2022
EP
US
WO
3 publications
Methods of treating heart failure with preserved ejection fraction
US 11617754 B2Applicant: POXEL SAPriority: 2017
CN
US
2 publications
ADENOSINE TRIPHOSPHATE SECRETION INHIBITOR, HEPATIC STELLATE CELL ACTIVATION INHIBITOR, HEPATIC STELLATE CELL DEACTIVATOR, HEPATIC FIBROSIS THERAPEUTIC AGENT, NON-ALCOHOLIC STEATOHEPATITIS THERAPEUTIC AGENT, PSORIASIS THERAPEUTIC AGENT, AND USE OF COMPOUND FOR PRODUCING ADENOSINE TRIPHOSPHATE SECRETION INHIBITOR, HEPATIC STELLATE CELL ACTIVATION INHIBITOR, HEPATIC STELLATE CELL DEACTIVATOR, HEPATIC FIBROSIS THERAPEUTIC AGENT, NON-ALCOHOLIC STEATOHEPATITIS THERAPEUTIC AGENT, AND PSORIASIS THERAPEUTIC AGENT
EP 4696306 A1Applicant: UNIV KURUMEPriority: 2023
EP
WO
2 publications
Methods of treating subjects having diabetes with chronic kidney disease
US 11266652 B2Applicant: POXEL SAPriority: 2020
US
2 publications
Imeglimin for preventing and/or treating hepatocellular carcinoma
US 11324752 B2Applicant: JANIN ERICPriority: 2017
US
A PROCESS FOR THE PREPARATION OF IMEGLIMIN COMPOUNDS
WO 2025233968 A1Applicant: COUNCIL SCIENT IND RESPriority: 2024
WO
SOLID COMPOSITIONS COMPRISING IMEGLIMIN
WO 2026142513 A1Applicant: LIVA ILAC PAZARLAMA SANAYI VE TICARET A SPriority: 2024
WO
METHOD FOR PRODUCING TRIAZINE DERIVATIVE, AND INTERMEDIATE FOR PRODUCTION OF SAID DERIVATIVE
WO 2026160418 A1Applicant: SUMITOMO PHARMA CO LTDPriority: 2025
WO